Safety and Efficacy of Docetaxel Plus Cisplatin Versus Cisplatin Concurrent with Radiation in Local Advanced Cervical Cancer: Midterm Results of A Phase III, Multicenter and Randomized Trial
Y. Zhang,M. Shi,L. Wei,J. He,Y. Zhu,W. Ma,Y. Yang,H. Zhao,X. Jia,X. Sun,L. Ran,G. Hao,Y. Ai,Y. Wang,T. Wang,L. Du,Q. Tang,Q. Si,C. Yue,G. Cheng
DOI: https://doi.org/10.1016/j.ijrobp.2019.06.1761
2019-01-01
Abstract:To assess the midterm safety and efficacy of concurrent and adjuvant docetaxel plus cisplatin triweekly chemotherapy compared with current standard of cisplatin weekly in locally advanced cervical cancer radiation. Eligible chemotherapy- and radiotherapy-naive cervical cancer patients with stage IB2 to IVA disease and Eastern Cooperative Oncology Group performance status 0-1 were randomly assigned to cisplatin 60 mg/m2 and docetaxel 60 mg/m2 triweekly with concurrent external-beam radiotherapy (XRT), followed by brachytherapy (BCT), and then two adjuvant 21-days cycles of cisplatin 75 mg/m2 and docetaxel 75 mg/m2 or to cisplatin (DDP) 40 mg/m2 weekly and concurrent XRT followed by BCT only. Between June 2016 and September 2018, 373 patients were enrolled (DDP, n=185; DP, n=172). The follow-up phase lasted until December 2018; median follow-up time was 30 months. During XRT, 161 patients (93.6%) received 2 cycle of DP concurrent chemotherapy, and 154 (89.5%) patients completed at least one cycle of adjuvant chemotherapy. There was no significant difference between two groups in radiotherapy duration. Compared with standard cisplatin, incidence of Grade 3 and 4 acute leukopenia and enteritis increased during DP concurrent chemoradiation (leucopenia, 24.3% vs 35.2%, P =0.042; enteritis, 4.2% vs 14.2%, P =0.003), but is quickly reversed clinically. The 2-yrs PFS was decreased in DDP group (75.0%) versus DP group (84.4%), but this difference was not statistically significant (HR:0.846, 95%CI:0.421-1.704;P=0.640). OS at 2 years was 89.9% and 89.3% in two groups respectively and the difference was not significant (P=0.369). Docetaxel plus cisplatin concurrent chemotherapy combined with adjuvant chemotherapy is clinically well tolerated. Compared with standard treatment, DP chemoradiotherapy increased acute toxicity but is clinically manageable. Survival effects have not been observed due to fewer clinically positive events.